See more : Forside Co.,Ltd. (2330.T) Income Statement Analysis – Financial Results
Complete financial analysis of Alexander’s, Inc. (ALX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alexander’s, Inc., a leading company in the REIT – Retail industry within the Real Estate sector.
You may be interested
- EGing Photovoltaic Technology Co.,Ltd. (600537.SS) Income Statement Analysis – Financial Results
- EDP – Energias de Portugal, S.A. (EDPFY) Income Statement Analysis – Financial Results
- Oasis Petroleum Inc. (OASPW) Income Statement Analysis – Financial Results
- Eastern Water Resources Development and Management Public Company Limited (EASTW-R.BK) Income Statement Analysis – Financial Results
- eFFECTOR Therapeutics, Inc. (EFTR) Income Statement Analysis – Financial Results
Alexander's, Inc. (ALX)
About Alexander's, Inc.
Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 224.96M | 205.81M | 206.15M | 199.14M | 226.35M | 232.83M | 230.57M | 226.94M | 207.92M | 200.81M | 196.46M | 191.31M | 204.27M | 183.83M | 168.38M | 163.85M | 170.01M | 179.58M | 139.18M | 110.15M | 75.45M | 55.48M | 69.14M | 43.67M | 47.80M | 22.50M | 21.60M | 25.20M | 2.50M | 13.20M | 4.90M | 2.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 101.21M | 90.45M | 21.14M | 88.40M | 89.74M | 93.78M | 85.13M | 82.23M | 76.22M | 69.90M | 64.68M | 61.76M | 84.94M | 78.65M | 73.34M | 77.11M | 70.50M | 71.98M | 64.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 123.75M | 115.37M | 185.01M | 110.74M | 136.61M | 139.05M | 145.45M | 144.70M | 131.70M | 130.92M | 131.78M | 129.56M | 119.33M | 105.18M | 95.04M | 86.74M | 99.51M | 107.60M | 74.30M | 110.15M | 75.45M | 55.48M | 69.14M | 43.67M | 47.80M | 22.50M | 21.60M | 25.20M | 2.50M | 13.20M | 4.90M | 2.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 55.01% | 56.05% | 89.75% | 55.61% | 60.35% | 59.72% | 63.08% | 63.76% | 63.34% | 65.19% | 67.08% | 67.72% | 58.42% | 57.21% | 56.44% | 52.94% | 58.53% | 59.92% | 53.39% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.28 | 0.63 | 0.21 | 0.39 | 0.36 | 0.35 | 0.38 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.34M | 6.11M | 5.92M | 6.31M | 5.77M | 5.34M | 5.25M | 5.44M | 5.41M | 5.03M | 5.28M | 5.16M | 84.94M | 86.44M | 101.59M | 91.68M | -38.34M | 154.84M | 32.39M | 81.29M | 48.92M | 3.96M | 3.86M | 3.89M | 3.70M | 4.10M | 3.90M | 4.40M | 5.10M | 3.60M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.34M | 6.11M | 5.92M | 6.31M | 5.77M | 5.34M | 5.25M | 5.44M | 5.41M | 5.03M | 5.28M | 5.16M | 84.94M | 86.44M | 101.59M | 91.68M | -38.34M | 154.84M | 32.39M | 81.29M | 48.92M | 3.96M | 3.86M | 3.89M | 3.70M | 4.10M | 3.90M | 4.40M | 5.10M | 3.60M | 1.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 120.24M | 124.03M | 120.76M | 121.09M | 126.86M | 120.05M | 116.04M | 107.30M | 99.09M | 93.66M | 90.57M | 3.06M | -3.44M | -29.59M | -4.68M | 93.34M | 94.16M | 84.61M | -184.58M | -128.43M | -12.97M | -23.14M | -20.93M | -28.40M | -17.60M | -4.60M | 9.00M | -3.50M | -9.50M | -4.10M | -134.90M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Operating Expenses | 6.34M | 126.35M | 129.95M | 127.07M | 126.86M | 132.20M | 125.30M | 121.48M | 112.71M | 104.13M | 98.94M | 95.73M | 88.00M | 83.00M | 72.00M | 87.00M | 55.00M | 249.00M | 117.00M | -103.30M | -79.51M | -9.01M | -19.28M | -17.04M | -24.70M | -13.50M | -700.00K | 13.40M | 1.60M | -5.90M | -2.90M | -134.90M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Cost & Expenses | 107.55M | 126.35M | 129.95M | 127.07M | 126.86M | 132.20M | 125.30M | 121.48M | 112.71M | 104.13M | 98.94M | 95.73M | 88.00M | 83.00M | 72.00M | 87.00M | 55.00M | 249.00M | 117.00M | -103.30M | -79.51M | -9.01M | -19.28M | -17.04M | -24.70M | -13.50M | -700.00K | 13.40M | 1.60M | -5.90M | -2.90M | -134.90M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Interest Income | 22.25M | 6.77M | 639.00K | 2.67M | 8.24M | 12.55M | 6.72M | 3.31M | 5.95M | 2.43M | 1.53M | 177.00K | 2.67M | 851.00K | 2.85M | 15.22M | 27.35M | 28.26M | 14.77M | 1.57M | 1.98M | 2.18M | 3.24M | 1.12M | 1.00M | 1.00M | 700.00K | 2.90M | 1.70M | 4.80M | 700.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 58.30M | 28.60M | 19.69M | 24.20M | 38.90M | 44.53M | 31.47M | 22.24M | 24.24M | 32.07M | 44.54M | 45.65M | 52.66M | 58.37M | 57.99M | 62.47M | 65.32M | 71.98M | 62.68M | 40.32M | 13.69M | 22.89M | 22.47M | 21.42M | 17.60M | 15.10M | 13.40M | 13.90M | 13.20M | 3.30M | 900.00K | 0.00 | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Depreciation & Amortization | 32.90M | 126.35M | 126.47M | 135.67M | 108.54M | 116.23M | 95.00M | 92.59M | 33.67M | 31.92M | 31.40M | 36.36M | 37.09M | 34.85M | 30.45M | 26.72M | 24.99M | 24.46M | 22.84M | 18.82M | 11.31M | 8.97M | 7.97M | 8.05M | 7.50M | 5.70M | 4.50M | 4.10M | 4.70M | 2.30M | 800.00K | 5.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 117.41M | 117.69M | 111.43M | 109.86M | 144.25M | 139.67M | 150.66M | 139.27M | 126.29M | 125.89M | 126.50M | 87.10M | 170.69M | 158.03M | 184.44M | 166.42M | 0.00 | 3.95M | 167.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 2.80M | 0.00 | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| EBITDA Ratio | 52.19% | 57.18% | 54.05% | 55.17% | 63.73% | 65.14% | 65.34% | 63.96% | 64.85% | 65.26% | 66.39% | 69.06% | 83.56% | 85.96% | 109.54% | 101.57% | 120.38% | 18.23% | 120.53% | 23.30% | 9.62% | 99.92% | 83.64% | 79.40% | 64.02% | 65.33% | 117.59% | 169.44% | 352.00% | 72.73% | 57.14% | -5,763.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 51.62M | 86.23M | 76.84M | 74.74M | 107.73M | 100.62M | 105.27M | 105.46M | 95.21M | 96.69M | 97.52M | 95.58M | 133.60M | 123.18M | 154.00M | 139.70M | 179.66M | 8.27M | 144.92M | 6.85M | -4.05M | 46.47M | 49.86M | 26.62M | 23.10M | 9.00M | 20.90M | 38.60M | 4.10M | 7.30M | 2.00M | -132.70M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Operating Income Ratio | 22.94% | 41.90% | 37.27% | 37.53% | 47.60% | 43.22% | 45.66% | 46.47% | 45.79% | 48.15% | 49.64% | 49.96% | 65.41% | 67.01% | 91.46% | 85.27% | 105.68% | 4.61% | 104.13% | 6.22% | -5.37% | 83.76% | 72.11% | 60.97% | 48.33% | 40.00% | 96.76% | 153.17% | 164.00% | 55.30% | 40.82% | -6,031.82% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 50.80M | -21.83M | 21.45M | -21.54M | -70.77M | -77.06M | 0.00 | -18.94M | -18.29M | -29.63M | -43.01M | -45.48M | -49.99M | -58.76M | -55.15M | -47.26M | -39.14M | -36.39M | -163.61M | -66.43M | -25.00M | -31.86M | -30.44M | -29.47M | -25.10M | -20.80M | -17.90M | -18.00M | -13.20M | -5.60M | -900.00K | 118.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 102.41M | 57.63M | 130.58M | 41.94M | 60.08M | 56.65M | 80.51M | 86.53M | 76.92M | 67.06M | 54.50M | 50.11M | 80.94M | 64.80M | 96.01M | 77.23M | 114.34M | -63.71M | 21.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -9.10M | 0.00 | 1.10M | -14.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 45.52% | 28.00% | 63.34% | 21.06% | 26.54% | 24.33% | 34.92% | 38.13% | 36.99% | 33.39% | 27.74% | 26.19% | 39.63% | 35.25% | 57.02% | 47.14% | 67.26% | -35.48% | 15.30% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -364.00% | 0.00% | 22.45% | -659.09% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 28.60M | 17.34M | 24.20M | 38.90M | 4.00K | 3.00K | 48.00K | 8.00K | -341.00K | -160.00K | 64.00K | -105.00K | -2.64M | -36.94M | 941.00K | 65.32M | 11.27M | 62.68M | 40.32M | 13.69M | 22.89M | 22.47M | 21.42M | 17.60M | 15.10M | 13.40M | 13.90M | -1.40M | 3.30M | 200.00K | 100.00K | 4.20M | 3.90M | -20.90M | 4.30M | -1.30M | -2.70M |
| Net Income | 102.41M | 29.03M | 132.93M | 17.74M | 21.17M | 32.84M | 80.51M | 86.48M | 76.91M | 67.93M | 56.92M | 674.39M | 79.42M | 66.43M | 132.19M | 76.29M | 114.34M | -74.98M | 82.24M | -33.47M | -17.74M | 23.58M | 27.39M | 5.20M | 5.50M | -6.10M | 7.50M | 24.70M | 2.40M | 4.00M | 900.00K | -132.80M | -4.20M | -3.90M | 20.90M | -4.30M | 1.30M | 2.70M |
| Net Income Ratio | 45.52% | 14.10% | 64.48% | 8.91% | 9.35% | 14.11% | 34.92% | 38.11% | 36.99% | 33.82% | 28.97% | 352.51% | 38.88% | 36.14% | 78.51% | 46.56% | 67.26% | -41.76% | 59.09% | -30.39% | -23.51% | 42.51% | 39.61% | 11.90% | 11.51% | -27.11% | 34.72% | 98.02% | 96.00% | 30.30% | 18.37% | -6,036.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 19.97 | 5.66 | 25.49 | 3.46 | 4.14 | 6.42 | 15.74 | 16.91 | 15.04 | 13.29 | 11.14 | 132.04 | 15.55 | 13.01 | 25.90 | 15.05 | 22.68 | -14.92 | 16.38 | -7.55 | -3.55 | 4.72 | 5.48 | 1.04 | 1.10 | -1.21 | 1.49 | 4.94 | 0.49 | 0.81 | 1.88 | -26.69 | -0.84 | -0.79 | 4.20 | -0.86 | 0.27 | 0.59 |
| EPS Diluted | 19.97 | 5.66 | 25.49 | 3.46 | 4.14 | 6.42 | 15.74 | 16.91 | 15.04 | 13.29 | 11.14 | 132.04 | 15.55 | 13.01 | 25.89 | 14.96 | 22.44 | -14.92 | 16.19 | -7.55 | -3.55 | 4.72 | 5.48 | 1.04 | 1.10 | -1.21 | 1.49 | 4.94 | 0.49 | 0.81 | 1.88 | -26.69 | -0.84 | -0.79 | 4.20 | -0.86 | 0.27 | 0.59 |
| Weighted Avg Shares Out | 5.13M | 5.13M | 5.12M | 5.12M | 5.12M | 5.12M | 5.12M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.10M | 5.07M | 5.04M | 5.03M | 5.02M | 4.43M | 5.00M | 5.00M | 5.00M | 5.00M | 5.00M | 5.04M | 5.03M | 5.00M | 4.90M | 4.94M | 5.00M | 4.98M | 5.00M | 4.94M | 4.98M | 5.00M | 4.81M | 4.58M |
| Weighted Avg Shares Out (Dil) | 5.13M | 5.13M | 5.12M | 5.12M | 5.12M | 5.12M | 5.12M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.11M | 5.10M | 5.10M | 5.03M | 5.08M | 4.43M | 5.00M | 5.00M | 5.00M | 5.02M | 5.02M | 5.04M | 5.03M | 5.00M | 5.00M | 5.00M | 5.00M | 4.98M | 5.00M | 4.94M | 4.98M | 5.00M | 4.81M | 4.58M |
ALX Resources Corp. Receives Shareholder Approval for the Previously Announced Plan of Arrangement with Greenridge Exploration Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - December 2, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to...
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
Alexander's Is A Good Business That The Market Has Overestimated
Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting...
A Decisive Realignment
U.S. equity markets soared to record highs this week after President-elect Trump scored a surprisingly decisive election victory, including a likely "trifecta" of Republican legislative control in Congress. The outcome sparked powerful moves across global financial markets as investors priced...
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend...
ALX Resources Corp. Announces Filing and Mailing of the Management Information Circular in Connection with Its Annual and Special Meeting of Shareholders to Approve the Acquisition of the Company by Greenridge Exploration Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, British Columbia--(Newsfile Corp. - November 7, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce...
Alexander's (ALX) Tops Q3 FFO and Revenue Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.
Alexander's Announces Third Quarter Financial Results
PARAMUS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended September 30, 2024 today and reported:
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual HER2-targeted bispecific antibody, in patients with advanced breast cancers Poster presentation will highlight new data from...
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
PARAMUS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on November 29, 2024 to stockholders of record on November 11,...
Source: https://incomestatements.info
Category: Stock Reports